Guselkumab for the treatment of psoriasis

Tildrakizumab for treating psoriasis

(2017) Marco Galluzzo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The role of IL 23 in the treatment of psoriasis

(2017) Lluís Puig   Expert Review of Clinical Immunology

Psoriasis and comorbid diseases

(2017) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis

(2017) G. Girolomoni et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis

(2017) Caleb Jeon et al.   Human Vaccines & Immunotherapeutics

Incidence, prevalence and mortality of patients with psoriasis: a U.K. population-based cohort study

(2016) D.A. Springate et al.   BRITISH JOURNAL OF DERMATOLOGY

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Psoriatic arthritis and psoriasis: differential diagnosis

(2016) Maddalena Napolitano et al.   CLINICAL RHEUMATOLOGY

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis

(2016) Yanli Zhuang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Current status and future prospects for biologic treatments of psoriasis

(2016) Abigail Cline et al.   Expert Review of Clinical Immunology

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Immunopathogenesis of Psoriasis

(2015) Jaehwan Kim et al.   DERMATOLOGIC CLINICS

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26

(2015) Stephan Meller et al.   NATURE IMMUNOLOGY

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation

(2015) Nicola Balato et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

(2015) Steven R. Feldman et al.   Journal of Managed Care & Specialty Pharmacy

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Protective Immunity to Systemic Infection with Attenuated Salmonella enterica serovar Enteritidis in the Absence of IL-12 Is Associated with IL-23-Dependent IL-22, but Not IL-17

(2014) S. M. Schulz et al.   JOURNAL OF IMMUNOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Educational and motivational support service: a pilot study for mobile-phone-based interventions in patients with psoriasis

(2012) N. Balato et al.   BRITISH JOURNAL OF DERMATOLOGY

Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State

(2012) Michele W. L. Teng et al.   CANCER RESEARCH

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-12 and IL-23 Affect Photocarcinogenesis Differently

(2012) Christian Jantschitsch et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

(2012) Rosa Parisi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

EADV preceptorship: advances in dermatology

(2010) W-H Boehncke et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interplay between keratinocytes and immune cells—Recent insights into psoriasis pathogenesis

(2008) Giulia Tonel et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY